tbuckley/cabot-search huggingface dataset:
BM-34 * NEW USES OF OLD DRUGS FOR THE CLINICAL TREATMENT OF BRAIN METASTASES
Authors: T. Sundstrom, J. Varughese, F. Azuaje, L. Prestegarden, K. Petersen, C. Tepper, E. Ingham, L. Even, S. Johnson, K. O. Skaftnesmo, M. Lund-Johansen, R. Bjerkvig, K. Ferrara, F. Thorsen
Journal: Neuro-Oncology (2014)

Metastatic brain tumors are ten times more common than that of all other primary brain tumors combined. Since it is not likely that the metastatic process is based on single genetic events alone, there is a need to find out whether a combination of multiple genes could be responsible for malignant disbursement of cancer cells from the primary site to the brain, in order to develop new treatment strategies. Here, we explored a more global and preventive treatment approach to brain metastases using an established xenograft model. Mice were injected intracardially under ultrasound guidance and followed for eight weeks with whole-body BLI and brain MRI. Tumor-bearing brains, adrenals, ovaries, and femurs were harvested and enzymatically dissociated before sorting out tumor cells by flow cytometry. By using RNA sequencing followed by bioinformatics analysis, we were able to determine a set of 108 genes that were specific for brain metastases, as compared to the metastases from the other organs. We then queried the Connectivity Map database using our 108-gene signature for drugs that could induce an opposite gene expression profile in various cancer cell lines. Three of the top ten drugs, already in use for other clinical conditions, showed significant efficacy in monolayer assays on several metastatic cell lines. We then tested these drugs in vivo, after injecting brain metastatic cell lines intracardially into nod/scid mice. Daily treatment was started immediately, and the animals were followed with whole-body BLI and brain MRI for 10 weeks. The treated animals showed decreased brain metastasis burden, increased survival, and acceptable toxicity profiles. Our results demonstrate a previously unrecognized potential for drug repurposing in the treatment of patients at risk of developing brain metastases or with clinically occult micrometastatic disease. Finding new uses for old drugs can greatly expedite translation to clinical practice.
Mesenteric Varices Mimicking Right Lower Quadrant Inflammation on Hepatobiliary Imaging
Authors: DAVID M. KEADLE, DAWN LIGHT, JOHN M. BAUMAN
Journal: Clinical Nuclear Medicine (2001)

From the Departments of Nuclear Medicine* and Internal Medicine “G,”† Haemek Medical Center, Afula, Israel Received for publication August 21, 2000. Accepted October 23, 2000. Reprint requests: David M. Keadle, M.D., Department of Radiology, Madigan Army Medical Center, Tacoma, Washington 98431. E-mail: [email protected]
P999 Y90-RADIOEMBOLIZATION FOR INTERMEDIATE/ADVANCED HCC PATIENTS OUTSIDE THE CONVENTIONAL CRITERIA MAY BE DETRIMENTAL: A SINGLE CENTER EXPERIENCE
Authors: C. Sposito, A. Facciorusso, T. Camerini, C. Chiesa, M. Maccauro, C. Morosi, S. Bhoori, D. Citterio, V. Mazzaferro
Journal: Journal of Hepatology (2014)
P966 EVALUATION OF THE PREVENTIVE EFFECT OF LOW DOSE ENOXAPARIN, PENTOXIFYLLINE AND URSODEOXYCHOLIC ACID TO RADIATION INDUCED LIVER TOXICITY IN A PROSPECTIVE RANDOMIZED TRIAL
Authors: M. Seidensticker, R. Seidensticker, R. Damm, K. Mohnike, M. Pech, B. Sangro, P. Hass, P. Wust, S. Kropf, G. Gademann, J. Ricke
Journal: Journal of Hepatology (2014)
Abstract 3954: Identification of microRNAs epigenetically silenced in bladder cancer
Authors: Takashi Shimizu, Hiromu Suzuki, Hiroshi Kitamura, Eiichiro Yamamoto, Kohzoh Imai, Taiji Tsukamoto, Minoru Toyota
Journal: Cancer Research (2011)

Abstract Purpose: Bladder cancer is the one of the most common malignancies in the urothelial tract. MicroRNAs (miRNAs) are small, non-coding RNAs that control gene expression post-transcriptionally, either by degradation of target mRNAs or by inhibition of protein translation. MiRNAs are involved in cancer development and progression, acting as tumor suppressors or oncogenes. Recent studies have demonstrated a role of DNA methylation in silencing miRNAs in bladder cancer. The aim of current study is to identify bladder cancer-related miRNAs by screening epigenetically silenced miRNAs in bladder cancer. Materials &amp; Methods: Two bladder cancer cell lines (T-24, UM-UC3) were treated with or without 5-aza-2’deoxycytidine (5-aza-dC) and 4-phenylbutyric acid (4-PBA), and expression of mature miRNAs was examined using a TaqMan Low Density Array System. We used UCSC genome browser to examine if CpG islands are located in the proximal upstream of the miRNAs upregulated after drug treatment. Methylation-specific PCR (MSP) and bisulfite pyrosequencing were carried out to analyze methylation status of the miRNA genes in bladder cancer cell lines and primary bladder cancer specimens. Results: Of 664 miRNAs examined, 208 miRNAs were up-regulated (&amp;gt;5-fold) in T24 cells, and 200 miRNAs were up-regulated in UM-UC3 cells, respectively. Among the miRNAs, 146 were commonly up-regulated in both T-24 and UM-UC3 cells. Among those 146 miRNAs, 36 miRNAs contain CpG islands in their 5’ end of the genes, and further analyzed. Methylation-specific PCR (MSP) was carried out, and 12 miRNAs showed aberrant methylation in bladder cancer cell lines. Bisulfite pyrosequencing of these 12 miRNAs was carried out, and we identified hypermethylation of 12 miRNAs in cultured and primary bladder cancer specimens. Conclusions: Our results suggest that DNA methylation is associated with miRNAs silencing in bladder cancer, and that these miRNAs may have a role in the development and progression of bladder cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3954. doi:10.1158/1538-7445.AM2011-3954
Endoplicature de la poche gastrique après échec d'une chirurgie bariatrique: étude préliminaire
Authors: RL Vitte, E Chouillard, R Bou Farah
Journal: Endoscopy (2012)

L'echec pondéral après by-pass gastrique ou duodenal switch peut être du à une dilatation secondaire de la poche gastrique ou de l'anastomose gastro-jéjunale. Afin d'éviter la morbimortalité des reprises chirurgicales après chirurgiebariatrique, la réduction endoscopique de la poche gastrique par endoplicature a été proposée.
Radioimmunoassay of Chromogranin a in Plasma as a Measure of Exocytotic Sympathoadrenal Activity in Normal Subjects and Patients with Pheochromocytoma
Authors: Daniel T. O'Connor, Keevin N. Bernstein
Journal: New England Journal of Medicine (1984)

Chromogranin A is the major soluble protein stored and secreted by exocytosis, along with catecholamines, from vesicles in the adrenal medulla and sympathetic nerves. We investigated the possible use of chromogranin A as a probe of exocytotic sympathoadrenal activity, by developing a radioimmunoassay for chromogranin A purified from pheochromocytoma vesicles. In 18 normal recumbent men chromogranin A was present in plasma at a concentration of 129±12 ng per milliliter. The concentration varied with physiologic, pharmacologic, and pathologic changes in sympathoadrenal activity. It rose with standing and fell with recumbency, though it was not perturbed by brief dynamic exercise. It rose during brief vasodilation and fell during stimulation of nonexocytotic catecholamine release by tyramine and during ganglionic blockade. The plasma concentration of chromogranin A was elevated in 11 patients with pheochromocytoma (1614±408 ng per milliliter). The mean plasma half-life was 18.4 minutes. We conclude that both resting and activated sympathoadrenal tone in normal persons, as well as catecholamine secretion by pheochromocytoma, are at least in part exocytotic in mechanism and that chromogranin A may be a useful probe of exocytotic sympathoadrenal activity. (N Engl J Med 1984; 311:764–70.)
THE IMPACT OF PHARMACOTHERAPY ON LONG-TERM SURVIVAL AND STROKE AFTER HOSPITALIZATION FOR ATRIAL FIBRILLATION
Authors: George O. Tsoukas, Claudia Blais, Roxanne Gagnon, Denis Hamel, Mark Sherman, Natasha Garfield, Vidal Essebag, Thao Huynh
Journal: Journal of the American College of Cardiology (2015)
Syphilis reinfections pose problems for syphilis diagnosis in Antwerp, Belgium – 1992 to 2012
Authors: C Kenyon, L Lynen, E Florence, S Caluwaerts, M Vandenbruaene, L Apers, P Soentjens, M Van Esbroeck, E Bottieau
Journal: Eurosurveillance (2014)

Persons with multiple syphilis reinfections may play an important role in syphilis transmission. We analysed all syphilis tests carried out for people attending the HIV/sexually transmitted infection (STI) clinic at the Institute of Tropical Medicine, Antwerp, Belgium, from 1992 to 2012 to evaluate the extent to which syphilis reinfections were contributing to the syphilis epidemic in Antwerp. We then characterised the features of the syphilis infections in individuals with five or more episodes of syphilis. A total of 729 syphilis episodes were diagnosed in 454 persons. The majority of syphilis episodes occurred in people who had more than one episode of syphilis (445/729; 61%). A total of 10 individuals had five or more episodes of syphilis diagnosed over this period. All were men who have sex with men, HIV positive and on antiretroviral therapy. They had a total of 52 episodes of syphilis diagnosed and treated. In 38/42 of the episodes of repeat syphilis in these 10 individuals, they presented without any signs or symptoms of syphilis. Given that the majority of cases of incident syphilis in our clinic were persons with reinfections and that they frequently presented without signs of symptoms of syphilis, there is a strong case for frequent and repeated screening in all persons with a diagnosis of syphilis.
Abstract 1305: The proangiogenic role of brain-derived neurotrophic factor in tumor development
Authors: CT Lam, ZF Yang, ST Fan, RTP Poon
Journal: Cancer Research (2010)

Abstract Background and Aim: Hepatocellular carcinoma is a hypervascularized solid tumor which requires angiogenesis for its growth. Previous studies suggested that neurotrophins, such as brain-derived neurotrophic factor (BDNF), may serve as angiogenic factors. The involvement of BDNF in tumor angiogenesis, however, remains unclear. The present study aimed at elucidating the role of BDNF in regulating angiogenesis and tumor development. Materials and Methods: BDNF was overexpressed in a normal mouse endothelial cell line by transfection. The angiogenic properties, including proliferation, cell motility, invasiveness and cell survival, of the transfectants were subsequently assessed by MTT, cell migration, invasion and Annexin V labeling assays, respectively. Microarray analysis was performed to explore the BDNF-mediated angiogenic pathway. An in vivo cell co-injection model, using a mouse transformed hepatocyte cell line and BDNF transfectants, was used to study the role of BDNF in tumor development. Results: Firstly, overexpression of BDNF could promote endothelial cell proliferation, migration, invasion and survival. Secondly, the gene expression profiling data suggested that the BDNF-induced angiogenic effects could be attributed to a dozen of genes including transcription factors, cell adhesion molecules, chemokines and growth factors. Thirdly, the in vivo cell co-injection experiment showed that high BDNF-expressing endothelial cells are able to promote growth of tumors with significantly higher number of microvessels. On the other hand, knock-down of BDNF in a tumor-derived endothelial cell line by shRNAs impairs such tumor promoting effect. Conclusion: The present study showed that BDNF is crucial for tumor angiogenesis and may serve as a potential target for anti-angiogenic treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1305.
Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2)
Authors: G Martinelli, C Terragna, M Amabile, V Montefusco, N Testoni, E Ottaviani, A de Vivo, A Mianulli, E Trabacchi, G Saglio, S Tura
Journal: Leukemia (1999)
O5.05 * FLUORESCEIN-GUIDED REMOVAL OF HIGH-GRADE GLIOMAS WITH A DEDICATED FILTER ON THE SURGICAL MICROSCOPE: PRELIMINARY RESULTS OF THE FLUOGLIO STUDY
Authors: F. Acerbi, M. Broggi, C. Cavallo, E. Anghileri, M. Eoli, M. Schiariti, E. L. Corte, B. Pollo, C. Boffano, P. Ferroli
Journal: Neuro-Oncology (2014)

BACKGROUND: Fluorescein is a fluorescent tracer that can be used for many applications. It is able to accumulate in brain areas with blood-brain barrier disruption, and thus it can be considered an ideal dye for intraoperative visualization of high-grade gliomas (HGG). We report the preliminary results of a phase II trail (FLUOGLIO) on a new fluorescein-guided technique to remove HHG with a dedicated filter on the surgical microscope. METHODS: In September 2011 we started a prospective phase II-trial (FLUOGLIO) to evaluated safety and obtain initial indications about efficacy of fluorescein-guided surgery for HGG. Patients with suspected HGG amenable to complete resection of contrast-enhancing area were eligible to participate in this study. This report is based on the analysis of the short- and long-term results in 28 consecutive patients with HGG (age range 45-74 years), enrolled since September 2011. Fluorescein was intravenous (i.v.) injected after intubation (5-10 mg/Kg). Tumor was removed with microsurgical technique and fluorescence visualization by BLU400 or YELLOW560 filters on Pentero microscope (Carl Zeiss, Germany). The study was approved by our Ethical Committee and registered on the European Regulatory Authorities website (EudraCT No. 2011-002527-18). RESULTS: Median pre-operative tumor volume was 33.1 cm3 (2.4-87.8 cm3). We found no adverse reaction to fluorescein administration. Tumor was completely removed in 80% of the patients. Median follow-up was 10 months. 6 months Progression-free Survival (PFS) and median survival were respectively 71.4 % and 11 months. CONCLUSION: Our analysis suggested that fluorescein-guided technique with a dedicated filter on the surgical microscope is safe and allows high-rate of complete resection of contrast-enhanced tumor at the early post-operative MRI.
THU0424 A Three-Month Follow-Up of Arthritis in Chikungunya Fever
Authors: A. K. Gutierrez-Rubio, A. D. Magbitang, G. Z. Racaza, M. L. G. Dianongco, T. Natividad, E. G. Penserga
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Chikungunya virus (CHIKV) is a mosquito-borne alphavirus of the family <i>Togaviridae</i> transmitted to humans by the <i>Aedes</i> spp. mosquitoes, causing Chikungunya Fever (CHIKF). <h3>Objectives</h3> This study aims to describe the course and outcome of arthritis in patients with CHIKF seen over a 3-month period. <h3>Methods</h3> This is a prospective descriptive study. Fifty-one patients with fever, rash, and arthritis seen at the University of the Philippines-Philippine General Hospital and private arthritis clinics were collected from August - December 2012. Demographics and course of arthritis were described. <h3>Results</h3> Fifty-one patients, 38 females, 13 male, with a mean age of 38.76 (range 8-61) were diagnosed with CHIKF. All cases were from the Metropolitan Manila area. Of these, 13 had 3-4 family members affected. Twenty-two patients were either employed or were students. The most common presenting symptoms were fever (94.1%), arthritis (88.2%), and rash (88.2%). The most common joint areas involved were the ankles (68.9%), the wrists (42.2%) and the small joints of the hand (53.3%) (especially the first MCP joint), the knees (28.9%), the tarsals (15.6%) and the 1st MTP (11.1%). At week 6, 35 cases were seen; 28 (80%) had persistent arthritis. Eleven (31.4%) patients had arthritis lasting at least 8 weeks. At 12 weeks, 12 patients followed-up; 3 continued to have arthritis. Three cases (5.9%) had myalgia or tenosynovitis of the extensor tendons of the hands. At least half of the cases had to stop work due to arthritis. Twenty-one patients had (+) CHIKV IgM by ELISA, and 1 had (+) CHIKV PCR. Sixteen of these had chronic arthritis of 6 weeks or longer (range, 6 – 16). Treatment consisted of continuous NSAIDs for at least 2 weeks and some received steroids. <h3>Conclusions</h3> This is a report on a recent outbreak of CHIKF, manifesting as a triad of fever, rash, and arthritis, severe enough to cause work stoppage. More females were affected. At least a third had chronic form of rheumatoid arthritis-like polyarthritis. There were families with several members involved. Continuous NSAID coverage was needed and some had to be given steroids. <h3>References</h3> Pialoux G, Gaüzère BA, Jauréguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 2007; 7:319-27 <h3>Disclosure of Interest</h3> None Declared
Abstract LB-285: Regulation of therapy resistance in slow-cycling cancer cells
Authors: Nathan Moore, Amy Chen, Michal Kamionek, JeanMarie Houghton, Stephen Lyle
Journal: Cancer Research (2012)

Abstract Tumor recurrence after chemotherapy is a major cause of patient morbidity and mortality. Recurrences are thought to be due in part to small subsets of cancer cells that are better able to survive traditional forms of chemotherapy and thus drive tumor re-growth. The ability to isolate and better characterize these therapy-resistant cells is critical for the future development of targeted therapies aimed at achieving more robust and long-lasting responses. Slow-cycling stem cells are integral components of adult epithelial tissues and are required for tissue maintenance. These slow-cycling cells are inherently resistant to traditional forms of chemotherapy that primarily target actively cycling cells. Using a novel application for the proliferation marker CFSE, we have identified populations of slow-cycling, label-retaining cells (LRCs) in primary tumors and cancer cell lines. As predicted, quiescent LRCs exhibit a multi-fold increase in chemoresistance but retain the ability to re-enter the cell cycle. We further demonstrate the innovative application of CFSE to live sort slow-cycling tumor cells and begin to explore the mechanisms behind LRC resistance and survival. Using RT-PCR and immunoblotting, we have observed consistent over-expression of the CDK5 activator, p35, in LRCs of both primary tumor xenografts and in-vitro sphere cultures. While p35 is known to play an active role in neurogenesis, cell migration, and apoptosis within the developing brain, its role in tumor biology remains unclear. Manipulation of p35 expression affects cell cycle distribution, extent of the LRC pool, and cell survival when challenged with traditional forms of chemotherapy. Additionally, we demonstrate that alterations in p35 expression alters downstream CDK5 signaling and the activation state of BCL2. Combined, our data suggest a model whereby the CDK5/p35 complex acts to slow cell cycling speed and change expression of BCL2, promoting resistance to chemotherapy. Future p35 targeting, in combination with traditional forms of chemotherapy, may help to reduce recurrence rates and increase long-term patient survival. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-285. doi:1538-7445.AM2012-LB-285
STILL HIGH PREVALENCE OF PERSISTENT LIPID ABNORMALITIES AMONG CORONARY PATIENTS DESPITE CHRONIC STATIN THERAPY IN 2014: RESULTS OF DYSIS II ACS AND CHD
Authors: Anselm K. Gitt, Dominik Lautsch, Baishali Ambegaonkar, Martin Horack, Philippe Brudi, Jean Ferrières
Journal: Journal of the American College of Cardiology (2016)
Abstract 327: Altered expression of insulin receptor isoforms in breast cancer
Authors: Huang Jiaqi, Chris Morehouse, Katie Streicher, Brandon W. Higgs, Jin Gao, Raffaele Baffa, Czapiga Meggan, Anmarie Boutrin, Philip Brohawn, Wei Zhu, Theresa LaVallee, Yong Chang, Laura Richman, Bahija Jallal, Yihong Yao
Journal: Cancer Research (2011)

Abstract Human insulin receptor (INSR) isoform A (IR-A), one of the two primary isoforms of INSR, constitutes an important therapeutic target for the development of anticancer drugs. There is also crucial need to develop a quick and sensitive method to accurately measure each of the two isoforms in humans. A specific quantitative real-time PCR-based assay has been developed to distinguish IR-A from insulin receptor isoform B (IR-B). This assay provides greater sensitivity, reproducibility, and clinical applicability than previously established methodologies. We used this assay to evaluate the mRNA expression levels of the IR-A and IR-B as well as multiple tumor proliferation markers in breast tumor tissues. Results revealed a significant decrease in IR-B mRNA expression leading to a relative increase in IR-A mRNA proportion in tumor samples compared to normal breast tissue samples. We also identified a novel positive correlation between increased IR-A: IR-B mRNA ratio and cancer proliferation markers, including Ki67. Furthermore, we observed a statistically significant difference of IR-A: IR-B mRNA ratio between luminal-A and -B breast cancer subtypes. These results suggest that IR-A is the predominant isoform of insulin receptor in breast cancer and highlights the potential value of characterizing changes in the IR-A: IR-B mRNA ratio as a therapeutic indicator for drugs that target insulin growth factor. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 327. doi:10.1158/1538-7445.AM2011-327
Abstract 4287: M13-stabilized single-walled carbon nanotubes as nanoprobes for second near-infrared window fluorescent imaging of targeted tumors
Authors: Debadyuti Ghosh, Hyunjung Yi, Jifa Qi, Angela M. Belcher
Journal: Cancer Research (2012)

Abstract Second near-infrared (NIR) window light (950-1,400 nm) is attractive for in vivo fluorescence imaging due to its deep penetration depth in tissues and low tissue autofluorescence. Here we show genetically engineered multifunctional M13 phage can assemble fluorescent single-walled carbon nanotubes (SWNTs) and ligands for targeted fluorescence imaging of tumors. M13-SWNT probe is detectable in deep tissues even at a low dosage of 2 μg/mL and up to 2.5 cm in tissue-like phantoms. Moreover, targeted probes show specific and four-fold improved uptake in prostate specific membrane antigen positive prostate tumors compared to control non-targeted probes. This M13 phage-based second NIR window fluorescence imaging probe has great potential for specific detection and therapy monitoring of hard-to-detect areas. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4287. doi:1538-7445.AM2012-4287